Dr. Agarwal's Health Care Limited (NSE:AGARWALEYE)

India · Delayed Price · Currency is INR

481.05

-2.90 (-0.60%)

Jun 25, 2026, 3:29 PM IST

19.59% (1Y)

Market Cap	153.61B +37.1%
Revenue (ttm)	20.80B +21.6%
Net Income	1.33B +59.6%
EPS	4.18 +50.4%
Shares Out	316.96M
PE Ratio	115.94
Forward PE	83.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,500
Open	487.30
Previous Close	483.95
Day's Range	480.10 - 492.20
52-Week Range	385.70 - 568.00
Beta	n/a
Analysts	Buy
Price Target	545.00 (+13.29%)
Earnings Date	Aug 3, 2026

About Dr. Agarwal's Health Care

Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the tr... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 2010

Country India

Stock Exchange National Stock Exchange of India

Ticker Symbol AGARWALEYE

Full Company Profile

Financial Performance

In fiscal year 2026, Dr. Agarwal's Health Care's revenue was 20.80 billion, an increase of 21.57% compared to the previous year's 17.11 billion. Earnings were 1.33 billion, an increase of 59.59%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for AGARWALEYE stock is "Buy." The 12-month stock price target is ₹545.00, which is an increase of 13.29% from the latest price.

Price Target

₹545.00

(13.29% upside)

Analyst Consensus: Buy

Stock Forecasts